Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study

Rossetti, Andrea O.; Jeckelmann, Sandrine; Nový, Jan; Roth, Patrick; Stupp, Roger

doi:10.1093/neuonc/not170

Cited by 74 publications

(58 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall side-effects of levetiracetam in EBT are seen in 5–10% of patients, often of psychiatric nature, including psychosis, depression, and aggressive behavior (Merrell et al, 2010b; Rosati et al, 2010; Maschio et al, 2011b; Rossetti et al, 2014). On the other hand, levetiracetam shows improvement in cognitive functioning in both EBT and general epilepsy (Helmstaedter and Witt, 2008; de Groot et al, 2013).…”

Section: Antiepileptic Drug Therapymentioning

confidence: 99%

Epilepsy and brain tumors

Englot

Chang

Vecht

2016

Handbook of Clinical Neurology

188

138

View full text Add to dashboard Cite

Seizures are common in patients with brain tumors, and epilepsy can significantly impact patient quality of life. Therefore, a thorough understanding of rates and predictors of seizures, and the likelihood of seizure freedom after resection, is critical in the treatment of brain tumors. Among all tumor types, seizures are most common with glioneuronal tumors (70–80%), particularly in patients with frontotemporal or insular lesions. Seizures are also common in individuals with glioma, with the highest rates of epilepsy (60–75%) observed in patients with low-grade gliomas located in superficial cortical or insular regions. Approximately 20–50% of patients with meningioma and 20–35% of those with brain metastases also suffer from seizures. After tumor resection, approximately 60–90% are rendered seizure-free, with most favorable seizure outcomes seen in individuals with glioneuronal tumors. Gross total resection, earlier surgical therapy, and a lack of generalized seizures are common predictors of a favorable seizure outcome. With regard to anticonvulsant medication selection, evidence-based guidelines for the treatment of focal epilepsy should be followed, and individual patient factors should also be considered, including patient age, sex, organ dysfunction, comorbidity, or cotherapy. As concomitant chemotherapy commonly forms an essential part of glioma treatment, enzyme-inducing anticonvulsants should be avoided when possible. Seizure freedom is the ultimate goal in the treatment of brain tumor patients with epilepsy, given the adverse effects of seizures on quality of life.

show abstract

Section: Antiepileptic Drug Therapymentioning

confidence: 99%

Epilepsy and brain tumors

Englot

Chang

Vecht

2016

Handbook of Clinical Neurology

188

138

View full text Add to dashboard Cite

show abstract

“…Meanwhile, evidence continues to mount documenting both the effectiveness and safety of newer-generation AEDS, like levetiracetam, oxcarbazepine and pregabalin [152,[196][197][198][199][200][201][202][203][204]. Though direct comparisons against the older drugs are generally lacking, theoretical advantages include the lack of any effect on cytochrome P450, and the fact that these drugs generally target specific risk factors for tumour-induced seizures [81].…”

Section: Aeds For Seizure Controlmentioning

confidence: 99%

Seizures in Children with Brain Tumours — Epidemiology, Significance, Management, and Outcomes

Ranger¹,

Diosy²

2015

Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients With a Brain Tumor

View full text Add to dashboard Cite

“…Levetiracetam-Overall side-effects of levetiracetam in EBT are seen in 5-10% of patients, often of psychiatric nature, including psychosis, depression, and aggressive behavior (Merrell et al, 2010b;Rosati et al, 2010;Maschio et al, 2011b;Rossetti et al, 2014). On the other hand, levetiracetam shows improvement in cognitive functioning in both EBT and general epilepsy (Helmstaedter and Witt, 2008;de Groot et al, 2013).…”

Section: Adverse Effects Of Aedsmentioning

confidence: 99%

Epilepsy and Brain Tumors

Newton

Maschio²,

Pritikin³

2015

View full text Add to dashboard Cite

Seizures are common in patients with brain tumors, and epilepsy can significantly impact patient quality of life. Therefore, a thorough understanding of rates and predictors of seizures, and the likelihood of seizure freedom after resection, is critical in the treatment of brain tumors. Among all tumor types, seizures are most common with glioneuronal tumors (70-80%), particularly in patients with frontotemporal or insular lesions. Seizures are also common in individuals with glioma, with the highest rates of epilepsy (60-75%) observed in patients with low-grade gliomas located in superficial cortical or insular regions. Approximately 20-50% of patients with meningioma and 20-35% of those with brain metastases also suffer from seizures. After tumor resection, approximately 60-90% are rendered seizure-free, with most favorable seizure outcomes seen in individuals with glioneuronal tumors. Gross total resection, earlier surgical therapy, and a lack of generalized seizures are common predictors of a favorable seizure outcome. With regard to anticonvulsant medication selection, evidence-based guidelines for the treatment of focal epilepsy should be followed, and individual patient factors should also be considered, including patient age, sex, organ dysfunction, comorbidity, or cotherapy. As concomitant chemotherapy commonly forms an essential part of glioma treatment, enzyme-inducing anticonvulsants should be avoided when possible. Seizure freedom is the ultimate goal in the treatment of brain tumor patients with epilepsy, given the adverse effects of seizures on quality of life.

show abstract

Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study

Abstract: This study shows that LEV and PGB represent valuable monotherapy options in this setting, with very good antiepileptic efficacy and an acceptable tolerability profile, and provides important data for the design of a phase III trial.

Cited by 74 publications

References 32 publications

Epilepsy and brain tumors

Epilepsy and brain tumors

Seizures in Children with Brain Tumours — Epidemiology, Significance, Management, and Outcomes

Epilepsy and Brain Tumors

Contact Info

Product

Resources

About